
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals has demonstrated strong commercial performance, with its precision medicine segment generating $316 million in revenue during the second half of 2025, indicating solid demand driven by U.S. sales of its cancer imaging agent, Illuccix. The company reported positive top-line results for a study that could significantly expand its U.S. market footprint in prostate cancer diagnosis, presenting an additional addressable market of approximately $3.5 billion. Furthermore, Telix's ability to meet its 2025 revenue targets reflects effective execution and positions the company favorably amid high risks and notable upside opportunities in the radiopharmaceuticals sector.
Bears say
Telix Pharmaceuticals reported a net loss of $1.0 million or an earnings per share (EPS) of $(0.30), which was better than prior estimates but still highlights ongoing financial struggles amid significant operational risks. The company faces multiple challenges, including potential negative clinical outcomes with its lead therapeutic candidate, TLX591, and the possibility of delays in advancing its pipeline toward regulatory approval, which could hamper future revenue generation. Additionally, Telix is exposed to competitive pressures within the radiopharmaceutical market and faces liquidity risks that may further impact its long-term financial stability and increase dilution risk for shareholders.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares